What is US 11,236,070 about for asciminib?
US 11,236,070 is a U.S. patent covering steps and process-related subject matter connected to making or using asciminib (a cancer drug). The specific process details are defined by the claims in the patent text.
What “process” is claimed in US 11,236,070?
In patent filings, “process” language usually means one or more of the following (depending on what the claims say):
- A method for preparing asciminib or an asciminib-related intermediate
- A method for producing a formulation or final dosage form containing asciminib
- A method of purification or workup used during manufacturing
- Conditions (reagents, temperatures, times, sequences) that distinguish the claimed method from other manufacturing routes
To identify the exact process steps, you need to read the claims and at least the detailed description section for US 11,236,070.
Where can I read the actual text of US 11,236,070?
If you want the precise claimed process (the exact steps, parameters, and limitations), use a patent database entry for US 11,236,070 and read:
- The claims (this is where the legal “process” is defined)
- The independent claims first (they typically define the core process)
- Any dependent claims (they add specific embodiments or refinements)
How can I check whether this process is part of manufacturing or formulation?
Look in the claims and description for cues such as:
- “preparing,” “producing,” “reacting,” “isolating,” “purifying,” “crystallizing” (often manufacturing)
- “formulation,” “dosage form,” “tablet,” “capsule,” “suspension,” “solid dispersion” (often formulation)
- References to intermediates or specific chemical transformations (often synthesis/purification)
Is there a link to DrugPatentWatch for asciminib patents?
DrugPatentWatch tracks branded drug patents and exclusivity-related filings and can help connect US patents to the corresponding drug development and exclusivity landscape. You can check asciminib’s profile and related patent records here: https://www.drugpatentwatch.com/ [1]
---
Sources
[1] https://www.drugpatentwatch.com/